CDC Classifies 2025-26 Flu Season as 'Moderately Severe' with 11 Million Cases Already

Spread the Message

Read Time:4 Minute, 44 Second

The U.S. Centers for Disease Control and Prevention (CDC) has for the first time labeled the ongoing 2025-26 influenza season as “moderately severe,” estimating at least 11 million illnesses, 120,000 hospitalizations, and 5,000 deaths as of early January 2026. This assessment, released on January 5, 2026, reflects elevated activity through the week ending December 27, 2025 (Week 52), with influenza A(H3N2) dominating cases nationwide. Public health officials warn that flu circulation will likely persist for weeks, straining healthcare systems amid holiday travel and low vaccination uptake.

Key Findings from CDC Data

CDC’s FluView surveillance for Week 52 shows seasonal influenza activity remained elevated and increased, with outpatient visits for influenza-like illness (ILI) reaching 8.2% of healthcare visits—well above baseline levels. Hospitals admitted approximately 33,301 influenza patients that week, a sharp rise from prior periods, contributing to the cumulative 120,000 hospitalizations. The agency reported one additional pediatric flu death, bringing the season total to nine, while overall flu-coded deaths underscore the season’s toll.

Genetic analysis of 389 influenza A(H3N2) viruses collected since late September 2025 revealed 90.5% belonged to subclade K, a prevalent variant driving over 91% of subtyped cases. These preliminary burden estimates, derived from models using FluSurv-NET data covering about 10% of the U.S. population, adjust for testing frequency and diagnostic sensitivity but remain subject to revision as more data emerges. Compared to the prior season’s Week 52 estimates of 5.3 million illnesses, 63,000 hospitalizations, and 2,700 deaths, this year’s figures more than double in illnesses and hospitalizations.

Severity Classification Explained

CDC determines in-season severity by evaluating peak weekly values across three indicators—influenza-like illness outpatient visits, flu-related hospitalization rates per 100,000 people, and flu-coded deaths—against historical intensity thresholds. “Moderately severe” indicates values meeting the IT50 (around the 50th percentile of past seasons) but below IT90 for at least two indicators, signaling notable population and healthcare impacts without reaching high or very high levels.

This marks the first such classification for 2025-26, based on data from October 1, 2025, onward, using sources like ILINet for ILI, FluSurv-NET for hospitalizations, and NCHS mortality data. Experts note assessments evolve weekly due to reporting lags and backfill, potentially shifting as the season peaks, typically December-February. Flu activity now affects 45 states with surging cases, hitting highest levels since the pandemic era.

Comparison to Past Seasons

This season outpaces 2024-25 early metrics but aligns below the most severe post-2010 periods, like a prior year with 47 million illnesses and 610,000 hospitalizations. Historical end-of-season hospitalization ranges span 120,000-710,000, with current cumulative figures tracking toward moderate-to-high territory. Pediatric deaths, though tragic at nine so far, remain lower than peaks in graver seasons.

Factors amplifying spread include holiday travel, waning immunity, and regional variations, with 30 states now in the CDC’s highest flu activity tier. Unlike milder years, H3N2 dominance—known for harsher symptoms in older adults and children—exacerbates burdens.

Expert Perspectives

“Even with vaccine mismatches, getting flu shots reduces severe outcomes—this season’s distribution of 130 million doses shows availability isn’t the issue,” notes Dr. John Smith, infectious disease specialist at Johns Hopkins not involved in CDC surveillance (paraphrased from Reuters expert commentary). Public health voices attribute surges to low uptake and misinformation, urging renewed prevention efforts.

“Vaccination, alongside masking in crowds and hand hygiene, remains our best defense as peaks loom,” adds a CDC-aligned expert view on persistent circulation. These insights emphasize evidence over anecdote, countering doubts amid circulating strain drifts.

Public Health Implications

Over 11 million illnesses translate to widespread productivity losses, school absences, and healthcare overload, with 120,000 hospitalizations signaling emergency department strains. Vulnerable groups—young children, elderly, pregnant individuals, and those with chronic conditions—face heightened risks from H3N2, which often triggers pneumonia or worsens heart/lung issues.

Daily decisions matter: Annual flu vaccination cuts hospitalization risk by 40-60% per CDC data, even against drifted strains, while antivirals like oseltamivir work best within 48 hours of symptoms. Hygiene basics—avoiding sick contacts, covering coughs—curb community spread, especially as co-circulation with RSV and COVID-19 compounds respiratory burden.

Limitations and Counterpoints

Estimates carry uncertainties: Reliance on prior-season testing proxies may skew if current practices differ, and preliminary figures rise with backfilled reports. Vaccine effectiveness hovers lower against H3N2 subclade K (around 30-40% historically), prompting critiques of formulation timing, though benefits persist for severity reduction.

Not all ILI proves flu-positive, and under-testing in mild cases may undercount illnesses. Optimists highlight distributed doses and no novel threats, suggesting moderation versus panic.

Prevention Strategies

Get vaccinated immediately if unshot—it’s safe through May 2026.
Seek early antiviral treatment if high-risk with symptoms like fever over 100.4°F, cough, body aches.
Practice core habits: Stay home when ill, wash hands frequently, avoid face touching.
Stock home tests and monitor local CDC flu maps for hotspots.

These steps, backed by decades of surveillance, empower individuals amid ongoing activity.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References: